Canine symmetrical lupoid onychodystrophy: a retrospective study with particular reference to management.
The records of six dogs in which a diagnosis of symmetrical lupoid onychodystrophy (SLO) had been made were examined retrospectively. The age at onset ranged from six months to eight years. All the dogs had been presented with onycholysis, onychomadesis, onychalgia and onychodystrophy. The diagnosis of SLO was confirmed in all cases by histological examination. Histological features were similar in all cases and included hydropic degeneration of the basal cell layer, pigmentary incontinence and a cell-rich interface dermatitis. Response (defined as good, partial or failure) to various therapies was compared. Treatments (as initial therapy or following previous treatment failure) included essential fatty acids (EFA) (three cases), a combination of tetracycline and nicotinamide (four cases) and azathioprine and/or prednisolone (one case each). EFA therapy resulted in one good response, one partial and one failure, tetracycline and nicotinamide in two good responses, one partial and one failure, and azathioprine and/or prednisolone in one good and one partial response. Although all treatments were successful in some cases, none was universally effective.
Auxilia
S T
ST
Department of Veterinary Clinical Studies, The Royal Dick School of Veterinary Studies, The University of Edinburgh, The Hospital for Small Animals, Easter Bush Veterinary Centre, Roslin, Midlothian.
Hill
P B
PB
Thoday
K L
KL
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003872:Dermatitis / Q000175:diagnosis / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000175:diagnosis / Q000188:drug therapy*; D004285:Dogs; D004359:Drug Therapy, Combination; D005228:Fatty Acids, Essential / Q000627:therapeutic use; D005260:Female; D005533:Foot Dermatoses / Q000175:diagnosis / Q000188:drug therapy / Q000662:veterinary*; D006724:Hoof and Claw; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D009536:Niacinamide / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D013752:Tetracycline / Q000627:therapeutic use; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D005228:Fatty Acids, Essential; D007166:Immunosuppressive Agents; D009536:Niacinamide; D011239:Prednisolone; D013752:Tetracycline; D001379:Azathioprine